Effects of Tirzepatide, a Dual GIP and GLP-1 RA, on Lipid and Metabolite Profiles in Subjects With Type 2 Diabetes
The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
Context: Tirzepatide substantially reduced hemoglobin A1c (HbA1c) and body weight in subjects with type 2 diabetes (T2D) compared with the glucagon-like peptide 1 receptor agonist dulaglutide. Improved glycemic control was associated with lower circulating triglycerides and lipoprotein markers and improved markers of beta-cell function and insulin resistance (IR), effects only partially attributable to weight loss. Objective: Assess plasma metabolome changes mediated by tirzepatide. Design: Phase 2b trial participants were randomly assigned to receive weekly subcutaneous tirzepatide, dulaglutide, or placebo for 26 weeks. Post hoc exploratory metabolomics and lipidomics analyses were performed. Setting: Post hoc analysis. Participants: 259 subjects with T2D. Intervention(s): Tirzepatide (1, 5, 10, 15 mg), dulaglutide (1.5 mg), or placebo. Main Outcome Measure(s): Changes in metabolite levels in response to tirzepatide were assessed against baseline levels, dulaglutide, and placebo using multiplicity correction. Results: At 26 weeks, a higher dose tirzepatide modulated a cluster of metabolites and lipids associated with IR, obesity, and future T2D risk. Branched-chain amino acids, direct catabolic products glutamate, 3-hydroxyisobutyrate, branched-chain ketoacids, and indirect byproducts such as 2-hydroxybutyrate decreased compared to baseline and placebo. Changes were significantly larger with tirzepatide compared with dulaglutide and directly proportional to reductions of HbA1c, homeostatic model assessment 2-IR indices, and proinsulin levels. Proportional to metabolite changes, triglycerides and diglycerides were lowered significantly compared to baseline, dulaglutide, and placebo, with a bias toward shorter and highly saturated species. Conclusions: Tirzepatide reduces body weight and improves glycemic control and uniquely modulates metabolites associated with T2D risk and metabolic dysregulation in a direction consistent with improved metabolic health.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Saeedi, P., Petersohn, I., Salpea, P., Malanda, B., Karuranga, S., Unwin, N., Colagiuri, S., Guariguata, L., Motala, A. A., Ogurtsova, K., et al. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.107843 · Cited by 10,792
Newgard, C. B., An, J., Bain, J. R., Muehlbauer, M. J., Stevens, R. D., Lien, L. F., Haqq, A. M., Shah, S. H., Arlotto, M., Slentz, C. A., et al. (2009) · Cell Metabolism · doi:10.1016/j.cmet.2009.02.002 · Cited by 3,165
Self-citationMetabolite profiles and the risk of developing diabetes
Wang, T. J., Larson, M. G., Vasan, R. S., Cheng, S., Rhee, E. P., McCabe, E., Lewis, G. D., Fox, C. S., Jacques, P. F., Fernandez, C., et al. (2011) · Nature Medicine · doi:10.1038/nm.2307 · Cited by 3,143
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
Drucker, D. J. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.001 · Cited by 2,170
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096
Coskun, T., Sloop, K. W., Loghin, C., Alsina-Fernandez, J., Urva, S., Bokvist, K. B., Cui, X., Briere, D. A., Cabrera, O., Roell, W. C., et al. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.09.009 · Cited by 882
Self-citationFrias, J. P., Nauck, M. A., Van, J., Kutner, M. E., Cui, X., Benson, C., Urva, S., Gimeno, R. E., Milicevic, Z., Robins, D., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32260-8 · Cited by 815
Self-citationRhee, E. P., Cheng, S., Larson, M. G., Walford, G. A., Lewis, G. D., McCabe, E., Yang, E., Farrell, L., Fox, C. S., O’Donnell, C. J., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44442 · Cited by 647
Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
Willard, F. S., Douros, J. D., Gabe, M. B. N., Showalter, A. D., Wainscott, D. B., Suter, T. M., Capozzi, M. E., van der Velden, W. J. C., Stutsman, C., Cardona, G. R., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.140532 · Cited by 541
How May GIP Enhance the Therapeutic Efficacy of GLP-1?
Samms, R. J., Coghlan, M. P., & Sloop, K. W. (2020) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2020.02.006 · Cited by 419
Research works printed but not linked: 20
- Tschöp, 2016, Unimolecular polypharmacy for treatment of diabetes and obesity, Cell Metab., 24, 51, 10.1016/j.cmet.2016.06.021 · DOI · Paper page
- Asmar, 2016, Insulin plays a permissive role for the vasoactive effect of GIP regulating adipose tissue metabolism in humans, J Clin Endocrinol Metab., 101, 3155, 10.1210/jc.2016-1933 · DOI · Paper page
- Wilson, 2020, The dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes, Diabetes Obes Metab., 22, 2451, 10.1111/dom.14174 · DOI · Paper page
- Newgard, 2017, Metabolomics and metabolic diseases: where do we stand?, Cell Metab., 25, 43, 10.1016/j.cmet.2016.09.018 · DOI · Paper page
- White, 2019, Branched-chain amino acids in disease, Science., 363, 582, 10.1126/science.aav0558 · DOI · Paper page
- Gall, 2010, alpha-hydroxybutyrate is an early biomarker of insulin resistance and glucose intolerance in a nondiabetic population, PLoS One., 5, e10883, 10.1371/journal.pone.0010883 · DOI · Paper page
- Cobb, 2016, α-hydroxybutyric acid is a selective metabolite biomarker of impaired glucose tolerance, Diabetes Care., 39, 988, 10.2337/dc15-2752 · DOI · Paper page
- White, 2016, Branched-chain amino acid restriction in Zucker-fatty rats improves muscle insulin sensitivity by enhancing efficiency of fatty acid oxidation and acyl-glycine export, Mol Metab., 5, 538, 10.1016/j.molmet.2016.04.006 · DOI · Paper page
- Tulipani, 2016, Metabolomics-guided insights on bariatric surgery versus behavioral interventions for weight loss, Obesity (Silver Spring)., 24, 2451, 10.1002/oby.21686 · DOI
- Gu, 2020, Distinctive metabolomics patterns associated with insulin resistance and type 2 diabetes mellitus, Front Mol Biosci., 7, 609806, 10.3389/fmolb.2020.609806 · DOI
- White, 2020, Muscle-liver trafficking of BCAA-derived nitrogen underlies obesity-related glycine depletion, Cell Rep., 33, 108375, 10.1016/j.celrep.2020.108375 · DOI
- Flores-Guerrero, 2018, Plasma branched-chain amino acids and risk of incident type 2 diabetes: results from the PREVEND prospective cohort study, J Clin Med., 7, 10.3390/jcm7120513 · DOI
- Glynn, 2015, Impact of combined resistance and aerobic exercise training on branched-chain amino acid turnover, glycine metabolism and insulin sensitivity in overweight humans, Diabetologia., 58, 2324, 10.1007/s00125-015-3705-6 · DOI · Paper page
- McGarrah, 2020, Dietary branched-chain amino acid restriction alters fuel selection and reduces triglyceride stores in hearts of Zucker fatty rats, Am J Physiol Endocrinol Metab., 318, E216, 10.1152/ajpendo.00334.2019 · DOI
- Walejko, 2021, Branched-chain α-ketoacids are preferentially reaminated and activate protein synthesis in the heart, Nat Commun., 12, 1680, 10.1038/s41467-021-21962-2 · DOI
- Yoneshiro, 2019, BCAA catabolism in brown fat controls energy homeostasis through SLC25A44, Nature., 572, 614, 10.1038/s41586-019-1503-x · DOI · Paper page
- Wittemans, 2019, Assessing the causal association of glycine with risk of cardio-metabolic diseases, Nat Commun., 10, 1060, 10.1038/s41467-019-08936-1 · DOI
- Fonseca, 2019, Reductions in insulin resistance are mediated primarily via weight loss in subjects with type 2 diabetes on semaglutide, J Clin Endocrinol Metab., 10.1210/jc.2018-02685 · DOI · Paper page
- Samms, 2019, 1009-P: the dual GIP and GLP-1 receptor agonist tirzepatide regulates lipid and carbohydrate metabolism through GIPR in adipose tissue, 10.2337/db19-1009-P · DOI
- Frias, 2019, Efficacy and safety of an expanded dulaglutide dose range: a phase 2, placebo-controlled trial in patients with type 2 diabetes using metformin, Diabetes Obes Metab., 21, 2048, 10.1111/dom.13764 · DOI · Paper page
Cited by
Rosenstock, J., Frias, J., Jastreboff, A. M., Du, Y., Lou, J., Gurbuz, S., Thomas, M. K., Hartman, M. L., Haupt, A., Milicevic, Z., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01053-x · Cited by 423
Self-citationNauck, M. A., & D‘Alessio, D. A. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01604-7 · Cited by 407
Insulin resistance and cardiovascular disease
Kosmas, C. E., Bousvarou, M. D., Kostara, C. E., Papakonstantinou, E. J., Salamou, E., & Guzman, E. (2023) · Journal of International Medical Research · doi:10.1177/03000605231164548 · Cited by 385
Xu, X., Poulsen, K. L., Wu, L., Liu, S., Miyata, T., Song, Q., Wei, Q., Zhao, C., Lin, C., & Yang, J. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01119-3 · Cited by 359
Vanweert, F., Schrauwen, P., & Phielix, E. (2022) · Nutrition & Diabetes · doi:10.1038/s41387-022-00213-3 · Cited by 289
Metadata
- Authors
- Pirro, V., Roth, K. D., Lin, Y., Willency, J. A., Milligan, P. L., Wilson, J. M., Ruotolo, G., Haupt, A., Newgard, C. B., & Duffin, K. L.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2021-10-05
- Volume
- 107
- Issue
- 2
- Pages
- 363-378
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W3203975425
- Cited by
- 113
- References
- 21
- FWCI
- 12.31
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Funders
- Eli Lilly and Company
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effects of Tirzepatide, a Dual GIP and GLP-1 RA, on Lipid and Metabolite Profiles in Subjects With Type 2 Diabetes. https://app.cochat.ai/papers/10.1210/clinem/dgab722
- The paper
- Pirro, V., Roth, K. D., Lin, Y., Willency, J. A., Milligan, P. L., Wilson, J. M., Ruotolo, G., Haupt, A., Newgard, C. B., & Duffin, K. L. (2022). Effects of Tirzepatide, a Dual GIP and GLP-1 RA, on Lipid and Metabolite Profiles in Subjects With Type 2 Diabetes. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgab722
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.